Ajanta Pharma Limited

NSE: AJANTPHARM

Healthcare Healthcare

₹3,298.9

-0.90%EOD · 19 Oct

Ajanta Pharma Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹41,223 Cr

52W Range

₹3796 / ₹2382

Volume

37K

50.4% delivery

1Y Return

+35.5%

P/E Ratio

36.7

P/B Ratio

9.2

ROE

25.4%

Debt / Equity

5.87

Peers in Healthcare

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Ajanta Pharma Limited(this stock)	₹3,298.9	₹41,223 Cr	36.7	9.2	25.4%	1.91%
Divi's Laboratories LimitedDIVISLAB	₹9,087	₹2.41 L Cr	83.0	14.5	16.2%	0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM	₹4,558.7	₹1.73 L Cr	72.8	18.4	17.0%	0.83%
Laurus Labs LimitedLAURUSLABS	₹2,069	₹1.12 L Cr	101.8	21.0	17.7%	0.12%
Zydus Lifesciences LimitedZYDUSLIFE	₹1,113.9	₹1.11 L Cr	25.0	4.2	18.3%	0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP	₹7,700	₹1.11 L Cr	54.3	12.0	21.5%	0.25%
Aurobindo Pharma LimitedAUROPHARMA	₹1,621.4	₹93,292 Cr	26.1	2.6	9.9%	0.00%
Mankind Pharma LimitedMANKIND	₹2,253.2	₹93,067 Cr	46.0	5.8	12.4%	0.00%
Max Healthcare Institute LimitedMAXHEALTH	₹830	₹80,785 Cr	56.7	7.7	14.3%	0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice

65/100

Composite score: 40% quality, 30% valuation, 30% momentum

QualityGood · 60

ValuationAverage · 40

MomentumStrong · 95

High ROE (25.4%)

High debt load (D/E 5.9)

In confirmed uptrend (Stage 2)

Technical Indicators

Full analysis · objective math, not advice

Returns

-0.9%

-3.0%

-5.8%

-4.9%

+18.2%

+35.5%

Weinstein Stage

Stage 2 — Advancing (uptrend)

RSI (14)

34 Neutral

Trend Template

6/7strong

RS vs Nifty (3M)

-3.2pp

Moving Averages (price vs MA)

20-DMA

₹3475

below

50-DMA

₹3527

below

150-DMA

₹3242

above

200-DMA

₹3143

above

From 52W High

-13.1%

From 52W Low

+38.6%

Support (20D)

₹3270

Resistance (20D)

₹3759

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.